ASCO Ethical Guidance for the Practical Management of Oncology Drug Shortages
L'"American Society of Clinical Oncology" présente des recommandations pour la gestion éthique des pénuries d'anticancéreux
In early 2023, national shortages of generic chemotherapies used to treat many common cancers forced many hospitals and clinics to allocate drugs in scarcity. Shortages of chemotherapies such as cisplatin and carboplatin are an acute example of an ongoing problem, with professional societies,1 media, policy-makers, regulators, and the Biden administration2 calling for action and relief. Shortages that affect patients with cancer are not unique to antineoplastic therapies; they have also been subject to clinically significant shortages of pressors,3 benzodiazepines,4 and antibiotics,5 among others. Given the complexity of the problem and the long timeline toward solutions addressing supply chain, demand, and manufacturing challenges, chemotherapy shortages are likely to continue into the foreseeable future. Patients and oncologists will be faced with delays, waitlists, or suboptimal clinical options and outcomes.
Journal of Clinical Oncology , article en libre accès, 2022